Immunogenicity of HPV-vaccination in a reduced-dose schedule
- Conditions
- cervical cancerHPV10047438
- Registration Number
- NL-OMON53042
- Lead Sponsor
- RIVM
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 1305
In order to be eligible to participate in the cohort study among girls, a
subject must meet all of the following criteria:
- Vaccinated with the bivalent HPV vaccine (Cervarix)
- Received one-, two- (with at least five months interval) or three-doses
(0,1,6 months) of the
vaccine
- Born between 1997 and 2003
- Female
The inclusion criteria for the cohort study among boys are as follows:
- Vaccinated with the bivalent HPV vaccine (Cervarix)
- Received two-doses (with at least five months interval) of the vaccine
- Born in 2012
- Male
A potential subject who meets any of the following criteria will be excluded
from participation in this study:
- unknown or incorrect address
- participated in tolerability study and stated to no longer be approachable
for further research
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method